How I treat secondary acute myeloid leukemia ashpublications.org/blood/article-… #leusm #AML

#EHA2025 #EHA25 | Just arriving at European Hematology Association meeting - already starting with excellent, highly productive, intense discussions for future directions, future endpoints & thinking about novel mechanisms of #DiseaseModification for MPN field | #MPNSM Claire Harrison

Sustained benefits of rux+pelabresib over rux+placebo in 1L MF at week 72 in the phase 3 MANIFEST2 study. Especially good to see the difference between the arms in rates of leukemic transformation narrowing over time. #EHA25 #MPNSM

👉👉👉Just in time for #EHA2025 #EHA25 | Treatment patterns and blood count control in 10,112 patients with polycythemia vera: Expert Review of Hematology | ⁦Naveen Pemmaraju, MD⁩ et al #MPNSM ⁦MPN_Hub⁩ ⁦VJHemOnc⁩ ⁦MPN Research Foundation⁩ ⁦MPNCo&D Congress⁩ tandfonline.com/doi/full/10.10…

Deeply honoured to present at the EHA plenary session!

CONGRESS | #EHA25 | PRESENTATION Vikas Gupta Vikas Gupta Princess Margaret Cancer Centre discusses management of accelerated and blast phase #MPN (MPN-AP/BP). Genetic profile of blast phase MPN different to de novo AML, little clinical trial data available as patients not usually eligible.

CONGRESS | #EHA2025 | PRESENTATION John Mascarenhas, Icahn School of Medicine at Mount Sinai shares preliminary results from the dose-escalation cohorts of the phase I INCA33989-101 and -102 trials evaluating INCA33989, a novel mutant calreticulin-specific monoclonal antibody therapy, in patients with

CONGRESS | #EHA2025 | PRESENTATION María Queralt Salas Queralt Salas Hospital Clínic presents results from a prospective multicenter study which aimed to validate the HCT-FS as a reliable tool for stratifying adult candidates for allo-HSCT into fit, pre-frail, and frail

CONGRESS | #EHA2025 | PRESENTATION Beth Psaila, Beth Psaila, MRC WIMM, gives a talk about a mutCALR×CD3 antibody (INCA035784) binds mutant cells, activates T cells for targeted cancer cell elimination. Potent activity towards type 1 and type 2 mutCALR with in vivo efficacy in

IDAC vs HiDAC as post-induction consolidation in AML evidence.nejm.org/doi/pdf/10.105…

📝 A new study published in Bone Marrow Transplantation indicates that common barriers to HSCT in patients with TP53m AML include infection, concurrent other cancer, and relapse within <3 months post-remission. More news: aml-hub.com #AMLsm #leusm #MedEd

A real-world study validates the LSC17 score's ability to predict AML patient outcomes and identify high-risk patients who may benefit from more aggressive treatments, led by Drs. Jean Wang University Health Network Princess Margaret Cancer Centre, Tracy Murphy & Stanley Ng UC Irvine School of Medicine. doi.org/10.3324/haemat…

Single-cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML Differentiation: brnw.ch/21wU8hL Andy Zeng Princess Margaret Cancer Centre Research #AMLsm

Just a small insight into how the world sees Trump. 🎥 TikTok - vm.tiktok.com/ZNd95GvVd/

ENHANCE-2 study in P53+ AML 2 randomizations: Magro_AZA vs Ven_AZA Magro_AZA vs 7+3 ⭐️ magro_AZA did not improve OS ⭐️ magro_AZA did not have higher ORR ⭐️⭐️ OS was really low in all arms We need novel drugs for p53 mutated MN ashpublications.org/blood/article/…

#IntheSpotlight A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML brnw.ch/21wUNVw

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm ow.ly/PYLp50WEPbm #myeloidneoplasia

Published in Blood Cancer Journal! Our Princess Margaret Cancer Centre study on 68 R/R FLT3m AML patients treated with gilteritinib-based therapy is out! Watch for the triple-mutated cohort outcomes! nature.com/articles/s4140…

CONGRESS | #SOHO2025 | PRESENTATION Vikas Gupta Vikas Gupta Princess Margaret Cancer Centre discusses the key factors influencing the decision to proceed with allo-HSCT in #myelofibrosis. Decisions require risk stratification to identify appropriate candidates and timing of HSCT should

Join us to understand more about the optimal use of gilteritinib-based therapy for relapsed/refractory FLT3-positive AML. nature.com/articles/s4140… 📅 Sep 19, 2025, 9 AM ET 🔗 Register: networks.resonancehealth.org/networks/alrca…